Effect of ceftaroline on normal human intestinal microflora

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1811-1814

  Panagiotidis, Georgios ^a   Bäckström, Tobias ^a   Asker Hagelberg, Charlotte ^a   Jandourek, Alena ^b   Weintraub, Andrej ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Cerexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BIFIDOBACTERIACEAE; CANDIDA ALBICANS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG FECES LEVEL; ELECTROCARDIOGRAM; ENTEROCOCCUS; ESCHERICHIA COLI; FECES; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; LACTOBACILLUS; MALE; NAUSEA; PAIN; PLASMA; PRIORITY JOURNAL; SIDE EFFECT; TENDON PAIN; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; CEPHALOSPORINS; FECES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINES; MALE; MICROBIAL SENSITIVITY TESTS; REFERENCE VALUES; YOUNG ADULT;

EID: 77951248359     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01716-09     Document Type: Article

References (11)

1. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
2. CLSI. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 7th ed. Approved standard M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Ge, Y., D. Biek, G. H. Talbot, and D. F. Sahm. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407.
4. Huang, H., A. Weintraub, H. Fang, and C. E. Nord. 2009. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections. J. Clin. Microbiol. 47:3729-3731.
5. Murray, P. R., E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.). 2007. Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
6. Nord, C. E., G. Rasmanis, and E. Wahlund. 2006. Effect of dalbavancin on the normal intestinal microflora. J. Antimicrob. Chemother. 58:627-631.
7. Sader, H. S., T. R. Fritsche, K. Kaniga, Y. Ge, and R. N. Jones. 2005. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49:3501-3512.
8. Sullivan, Å., C. Edlund, and C. E. Nord. 2001. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 1:101-114.
9. Sullivan, Å., C. Edlund, and C. E. Nord. 2005. Interaction between antimicrobial agents and the oropharyngeal and intestinal microflora, p. 1357-1370. In A. Bryskier (ed.), Antimicrobial agents. ASM Press, Washington, DC.
10. Talbot, G. H., D. Thye, A. Das, and Y. Ge. 2007. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51:3612-3616.
11. Zhanel, G. G., G. Sniezek, F. Schweizer, S. Zelenitsky, P. R. S. Lagacé-Wiens, E. Rubinstein, A. S. Gin, D. J. Hoban, and J. A. Karlowsky. 2009. Ceftaroline. A novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 69:809-831.